Association of genetic variations and weight loss response to naltrexone/bupropion
Weight Loss Study: Genetic Variations and Response to Naltrexone/Bupropion
Sponsor: NIH
Enrolling: Male and Female Patients
Study Length: 40 Weeks
Clinic Visits: 6
IRB Number: AAAU3131
U.S. Govt. ID: NCT05919797
Contact: Sarah Borden: 212-305-4006 /
Additional Study Information: The purpose of this study is to evaluate if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The participation lasts ten months and includes six in-person visits at CUIMC with blood sampling and questionnaires, virtual nutritional counseling, and taking an oral weight loss medication for 28 weeks.
Judith Korner, MD
Do You Qualify?
Are you between the ages of 18 and 65? Yes No
Do you have diabetes? Yes No
Do you have a history of previous bariatric surgery? Yes No
Do you have obesity or are you overweight? Yes No
Do you live in the New York City tristate area (NY, NJ, CT)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Sarah Borden